Interviews

Tozorakimab targets IL-33 upstream of TH2 pathways, cutting COPD exacerbations up to 34% in former smokers, Frank Sciurba, MD, explained.

Laura Fabbri, MD, says patient wishes should guide care decisions in IPF and lung cancer overlap.

Francesca Polverino, MD, PhD, says COPD exacerbation severity lacks a clear definition, complicating GOLD's escalation criteria.

Yet H. Khor, MD, PhD, explains why the CPFE index can't replace CT imaging but may help triage which patients need scans.

Policy changes could have the greatest impact on transplant equity, explains hematologic oncologist Karilyn Larkin, MD.

Trejeeve Martyn, MD, shares why finerenone belongs on formulary, and how pharmacist-led access models can work in smaller health systems.

Follow-up length varied by subgroup in the MINT trial, but inebilizumab cut exacerbations and rescue therapy use consistently.

Coordinated networks—not isolated referrals—drove social care success in North Carolina and Ballad Health, says Halima Ahmadi-Montecalvo, PhD, MPH.

Optum Health's Ken Cohen, MD, FACP, discusses findings from a recent study linking elective PVI to higher limb loss and costs.

Francesca Puggioni, MD, explains how multidisciplinary teams choose COPD biologics and why systemic inflammation matters as much as FEV1.

The final part explores individualized CAR T and bispecific therapy selection in multiple myeloma and the need for stronger academic-community collaboration.

Andrew Kuykendall, MD, lead investigator for the VERIFY trial supporting the approval, said rusfertide is used to treat erythrocytosis in polycythemia vera.

Hospital resources, not clinical preference, often decide which MG rescue therapy a patient receives, Richard Nowak, MD, MS, said.

Nilesh Desai, MBA, RPh, on automation, AI, and building the health-system pharmacy enterprise of 2035

The PARADIGM trial excluded patients with NPM1 mutations, core binding factor alterations, and FLT-3–mutated disease, so the data should not apply to them.

In part 2, Christos Vaklavas, MD, discusses clinical trial complexity and the shift toward more accessible treatment delivery.

Scheduling apheresis, manufacturing the cells, and ultimately administering the treatment can take several weeks, Madhav Seshadri, MD, explains.

Amandeep Godara, MBBS, explained that rural patients with multiple myeloma face various barriers to immunotherapies that may delay treatment.

In this Director’s Cut episode of Managed Care Cast, we speak with Surbhi Sidana, MD, Stanford University, on the transformation of the myeloma field.

Christos Vaklavas, MD, discusses geographic and telehealth barriers to cancer care access across Utah and the broader Mountain West.

Amandeep Godara, MBBS, discusses how patient factors, disease burden, and logistics guide treatment decisions in relapsed/refractory multiple myeloma.

Shiven B. Patel, MD, MBA, discussed strategies for overcoming tissue limits, delays, and rural access gaps in NSCLC biomarker testing at an IVBM event.

Part D plans are navigating intensifying pressure from GLP-1 therapies, which combine relatively high per-patient costs with a massive eligible population.

Hepatitis B elimination requires expanded vaccination, screening, treatment, and education, Helen Nde, MPH, said.

Lymphomas arise from immune system cells and can create an environment less hospitable to CAR T-cell expansion, explained Kerry Rogers, MD.

Zidesamtinib offers a new second-line option for ROS1-positive NSCLC, with durable responses and strong activity against brain metastases.

Mark Makhinson, PharmD, launches Future-Proofing Pharmacy, exploring AI, access, and the health-system pharmacy enterprise of 2035.

For Xavier Leleu, MD, PhD, there is opportunity to ensure that therapeutic advances are accompanied by advances in how those therapies are delivered.